- Home
- UUU vs BCDA Comparison
UUU vs BCDA Comparison
Compare UUU & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UUU
- BCDA
- Stock Information
- Founded
- UUU 1969
- BCDA N/A
- Country
- UUU United States
- BCDA United States
- Employees
- UUU N/A
- BCDA N/A
- Industry
- UUU Electronic Components
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- UUU Technology
- BCDA Health Care
- Exchange
- UUU Nasdaq
- BCDA Nasdaq
- Market Cap
- UUU 12.6M
- BCDA 11.3M
- IPO Year
- UUU N/A
- BCDA N/A
- Fundamental
- Price
- UUU $4.38
- BCDA $1.29
- Analyst Decision
- UUU
- BCDA Strong Buy
- Analyst Count
- UUU 0
- BCDA 1
- Target Price
- UUU N/A
- BCDA $25.00
- AVG Volume (30 Days)
- UUU 111.7K
- BCDA 182.7K
- Earning Date
- UUU 11-19-2025
- BCDA 11-12-2025
- Dividend Yield
- UUU 22.42%
- BCDA N/A
- EPS Growth
- UUU N/A
- BCDA N/A
- EPS
- UUU 1.19
- BCDA N/A
- Revenue
- UUU $22,789,285.00
- BCDA N/A
- Revenue This Year
- UUU N/A
- BCDA N/A
- Revenue Next Year
- UUU N/A
- BCDA N/A
- P/E Ratio
- UUU $3.96
- BCDA N/A
- Revenue Growth
- UUU 30.84
- BCDA N/A
- 52 Week Low
- UUU $1.65
- BCDA $1.00
- 52 Week High
- UUU $8.27
- BCDA $3.20
- Technical
- Relative Strength Index (RSI)
- UUU 43.68
- BCDA 41.21
- Support Level
- UUU $4.30
- BCDA $1.27
- Resistance Level
- UUU $4.80
- BCDA $1.45
- Average True Range (ATR)
- UUU 0.50
- BCDA 0.09
- MACD
- UUU -0.08
- BCDA 0.00
- Stochastic Oscillator
- UUU 4.79
- BCDA 14.81
About UUU Universal Security Instruments Inc.
Universal Safety Products Inc is a U.S.-based importer and distributor of home safety devices such as ventilation fans and ground fault circuit interrupters.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).